JPRN-jRCT1080224072
已完成
未知
Biomarker study of Atezolizumab with Bevacizumab for Patients with PD-L1 High Expression Non-Small Cell Non-Squamous Cell Lung Cancer
Kaname Nosaki (Principal Investigator)0 个研究点目标入组 38 人2018年10月1日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- non-small-cell lung cancer
- 发起方
- Kaname Nosaki (Principal Investigator)
- 入组人数
- 38
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Patient enrolled into WJOG10718L (A Phase II Study of Atezolizumab with Bevacizumab for Patients with PD\-L1 High Expression Non\-Small Cell Non\-Squamous Cell Lung Cancer)
- •2\. Written informed consent to biomarker study
排除标准
- 未提供
结局指标
主要结局
未指定
相似试验
已完成
2 期
A Phase II Study of Atezolizumab with Bevacizumab for Patients with Non-Small Cell Non-Squamous Cell Lung Cancer (At Be Study) (Investigator-Initiated Clinical Trial)non-small-cell lung cancerJPRN-jRCT2080223980Takashi Seto (Coordinating Investigator)38
进行中（未招募）
2 期
Phase II study of atezolizumab plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma and Child-Pugh BHepatocellular carcinomaSystemic therapyJPRN-jRCTs031210355Ikeda Masafumi30
尚未招募
不适用
Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-UMIN000042750Gifu university first Dept of internalmedicine300
进行中（未招募）
2 期
Atezo+Bev study for pretreated patientshepatocellular carcinomaJPRN-jRCT1041200068Yamashita Tatsuya28
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEfficacy of atezolizumab in combination with non-platinum based chemotherapy and bevacizumab versus the combination of a non-platinum based chemotherapy and bevacizumab in recurrent ovarian cancerMedDRA version: 27.0Level: PTClassification code 10016182Term: Fallopian tube cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-000202-37-LTAGO Research GmbH550